Intra Cellular Therapies | ITCI - Ebitda



Ebitda Veränderung Datum
Acadia Pharmaceuticals USD 20.31M 15.44M 2025-12
ALKERMES USD 80.26M 20.05M 2026-03
BioCryst Pharmaceuticals USD 51.7M 30.14M 2025-09
Biogen USD 649.7M 76.5M 2026-03
Bristol-Myers Squibb USD 2.88B 1.36B 2025-12
Cytokinetics USD -169.32M 19.48M 2026-03
Esperion Therapeutics USD -9.93M 24.99M 2025-09
Gilead Sciences USD 3.02B 1.01B 2025-12
Halozyme Therapeutics USD 219.57M 197.66M 2026-03
J&J USD 7.19B 2.32B 2025-12
Minerva Neurosciences USD -4.36M 1.71M 2024-09
Nektar Therapeutics USD -31.81M 70K 2023-09
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Novartis USD 5.84B 235M 2025-09
Prothena USD -39.53M 12.25M 2025-09
RedHill Biopharma USD 2.69M 108.46M 2023-06
Supernus Pharmaceuticals USD 29.23M 19.27M 2026-03
United Therapeutics USD 379.5M 83.4M 2025-12
Vanda Pharmaceuticals USD -8.31M 2.37M 2024-12